DianeLaurenReidyMD

Physician

Overview of Dr. Reidy

Dr. Diane Reidy is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, New York-Presbyterian Hospital, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 17 years. She is one of 64 doctors at NYC Health + Hospitals / Bellevue and one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She also speaks multiple languages, including Spanish. She has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(716) 575-7986

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2001 - 2005
State University of New York Downstate Medical Center College of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2002 - 2026
NJ State Medical License 2020 - 2025
OK State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors Start of enrollment: 2008 Aug 01
Completed
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Start of enrollment: 2009 Feb 01
Completed
Phase 2
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) Start of enrollment: 2010 Jul 01
Completed
Phase 2
Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors Start of enrollment: 2012 May 14
Completed
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Start of enrollment: 2016 Feb 01
Active, not recruiting
Phase 2
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors Start of enrollment: 2017 Feb 27
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Long term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy.
Darren Cowzer, Kevin Soares, Henry Walch, Mithat Gönen, Taryn M Boucher
Journal of the National Cancer Institute. 2024-09-27
2 citations
A review of mitotane in the management of adrenocortical cancer.
Jaydira Del Rivero, Tobias Else, Julie Hallanger-Johnson, Katja Kiseljak-Vassiliades, Nitya Raj
The Oncologist. 2024-09-06
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.
E Baudin, J Capdevila, D Hörsch, S Singh, M E Caplin
Endocrine-Related Cancer. 2024-09-01

Journal Articles

Biodistribution and Radiation Dose Estimates for 68Ga-DOTA-JR11 in Patients with Metastatic Neuroendocrine Tumors
Simone Krebs, Lisa Bodei, Diane Reidy, Bradley J Beattie, Wolfgang A Weber, European Journal of Nuclear Medicine and Molecular Imaging

Authored Content

Gene Signature Associated with Upregulation of the Wnt/Β-catenin Signaling Pathway Predicts Tumor Response to Transarterial EmbolizationMarch 2018

Press Mentions

The Pandemic Is Leading to Missed Cancer Diagnoses, New Data WarnsDecember 17th, 2021
Westchester Healthcare Matures During the Coronavirus PandemicMay 26th, 2020
Ipsen : Neuroendocrine Tumor (NET) Expert CallMay 3rd, 2018
Join now to see all